文献速递心脑血管急症重症综合管理与镇静镇痛

托伐普坦在急性心力衰竭患者长途转运中的疗效与安全性

Efficacy and safety of tolvaptan in acute heart failure patients during long-distance transportation.
PubMed 文献 · Am J Emerg Med · 2021-10-06
一句话结论回顾性研究提示,急性心衰患者长途转运前使用托伐普坦安全,或可减少转运中氧疗升级、缩短ICU停留和氧疗及下床活动时间。

该回顾性研究纳入30例在稚内市立医院新诊断急性心衰并长途转运至名寄市立综合医院的患者,分为托伐普坦组(n=18)和对照组(n=12)。结果显示两组出院存活率无统计学差异(100% vs 91%,p=0.414);托伐普坦组转运期间需增加氧剂量的比例显著更低(0% vs 36%,p=0.0181),ICU停留时间更短(中位2天 vs 6天,p=0.0376),停氧时间更短(中位2.8天 vs 6.9天,p<0.00125),下床活动时间更短(中位1.5天 vs 7.5天,p=0.0362),转运期间心率显著降低(99±21 vs 88±21次/分,p=0.016)。结论认为长途转运的急性心衰患者使用托伐普坦安全,临床过程可能优于常规治疗。

要点

  • 急性心衰长途转运前使用托伐普坦者转运期间需增加氧剂量的比例为0%,显著低于对照组的36%(p=0.0181)。
  • 托伐普坦组ICU停留中位时间2天,显著短于对照组6天(p=0.0376)。
  • 托伐普坦组停氧中位时间2.8天、下床活动中位时间1.5天,均显著短于对照组(6.9天、7.5天;p<0.00125、p=0.0362)。
  • 两组出院存活率无统计学差异(100% vs 91%,p=0.414)。
  • 托伐普坦组转运期间心率显著降低(99±21 vs 88±21次/分,p=0.016),血压无差异。

适用人群与场景

  • 在稚内市立医院新诊断急性心衰并需长途转运至名寄市立综合医院ICU的患者,纳入2013年1月至2020年5月共30例。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及托伐普坦的具体剂量、给药途径、频次或疗程。
  • 对照组接受常规治疗,具体方案原文未提及。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 回顾性研究,纳入30例(托伐普坦组18例,对照组12例),单中心出发医院、单中心接收医院。
  • 主要终点出院存活率:托伐普坦组100% vs 对照组91%,p=0.414,无统计学差异。
  • 转运期间需增加氧剂量比例:0% vs 36%,p=0.0181。
  • ICU停留中位时间:2天 vs 6天,p=0.0376。
  • 停氧中位时间:2.8天 vs 6.9天,p<0.00125。
  • 下床活动中位时间:1.5天 vs 7.5天,p=0.0362。
  • 转运期间心率:99±21 vs 88±21次/分,p=0.016;血压无差异。

证据类型、等级与局限

  • 证据类型:回顾性研究。
  • 局限:样本量小(30例)、回顾性设计、非随机分组、单中心出发医院和单中心接收医院,原文未提及证据等级或推荐强度。

对床旁实践的改变

  • 对于需长途转运的急性心衰患者,可考虑转运前使用托伐普坦以降低转运期间氧疗升级风险,但需注意该结论来自小样本回顾性研究,不能作为常规推荐。
  • 原文未提及托伐普坦的具体剂量和给药方案,临床使用时不能直接套用本研究方案。
  • 原文未提及不适用人群或禁忌证,使用前需按药品说明书评估。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

AIMS: Treating patients with acute heart failure is difficult at the local hospitals in medically depopulated areas where cardiologists are generally absent. These patients require long-distance and time-consuming transportation to the intensive care units. It is well known that tolvaptan is effective for the treatment of congestive heart failure, but the effect of prehospital tolvaptan use in patients is not well evaluated. The aim of this study was to evaluate the efficacy and safety of prehospital tolvaptan use in patients with acute congestive heart failure who require long-distance and time-consuming transportation.

METHODS: This retrospective study included 30 patients who were newly diagnosed with acute heart failure at Wakkanai City Hospital and transported to Nayoro City General Hospital between January 2013 and May 2020. The patients were classified into those who received tolvaptan (tolvaptan group, n = 18) and did not receive tolvaptan (control group, n = 12).

RESULTS: The percentage of patient survival at discharge did not show a statistically significant difference between the groups (100% [tolvaptan] vs. 91% [control], p = 0.414). During transportation, the percentage of patients in the tolvaptan group who required increased oxygen doses was statistically significantly lower than that in the control group (0% vs. 36%, p = 0.0181). Patients in the tolvaptan group had statistically significantly shorter intensive care unit stays (median: 2 days vs. 6 days, p = 0.0376), less days to discontinuation of oxygen (median: 2.8 days vs. 6.9 days, p < 0.00125), and less days to ambulation (median: 1.5 days vs. 7.5 days, p = 0.0362) compared with the control group. In the tolvaptan group, blood pressure was not different; however, heart rate was statistically significantly reduced (99 ± 21 vs. 88 ± 21 beats per minute, p = 0.016) during transportation.

CONCLUSION: The use of tolvaptan in patients with acute heart failure requiring long-distance transport is safe and may show better clinical course compared with conventional therapies.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Iwata S, Yamaki M, Nishiura T, et al. Efficacy and safety of tolvaptan in acute heart failure patients during long-distance transportation. Am J Emerg Med. 2021. PMID: 34678574. doi:10.1016/j.ajem.2021.09.082

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。